Nasdaq Biotech ETF (IBB) Has Inched Closer To New Highs; What’s Next?
Over the years, the biotech sector has proven to be one of the fastest-growing sectors in the market and naturally investors have gravitated towards penny stocks in a big way. If market experts are to be believed then the biotech sector is expected to grow significantly in the foreseeable future as well. In such a situation, it is only natural for investors to invest in biotech stocks.
The biotech sector, as measured by the SPDR S&P Biotech (NYSE:XBI) is staging what could be a massive break out. The ETF has been trending lower since September 2018, with shares of the ETF declining by over 12%, versus an S&P 500 that has increased by over 7%.
Now the biotech ETF may be on the cusp of a big come back and may be about to surge by as much as 8%. Furthermore, the Nasdaq Biotech Index (IBB) has rallied back above $115 within striking distance of new 52-week highs.
That being said, one needs to watch the market closely in order to identify promising names. Here is a quick look at 3 penny stocks to watch in biotech at the end of this month.
Pharmacyte Biotech (PMCB) Hits Record Q4 Trading Volume
One of the gauges investors may use to put together a list of penny stocks is trading volume. For Pharmacyte Biotech (PMCB), its market has seen some of its most active sessions in the 4th quarter. On November 21 PMCB stock traded over 5.6 million shares in a range from $0.0332 to $0.0365. Much of this activity came after the company released news that could be its latest milestone.
Pharmacyte announced that its partner, Austrianova Singapore, has successfully completed the second and final GMP manufacturing run to produce PharmaCyte’s clinical trial product. The product is now ready for “release testing.”
What this means is that the data from the “release testing” of both manufacturing runs will be included in an Investigational New Drug application (IND) and submitted to the FDA. It will be used to support PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer (LAPC).
“Our GMP consultant, cGMP Validation, has informed us that while two successful manufacturing runs are not required by the FDA to request a Phase 2b clinical trial, it could go a long way in demonstrating to the FDA that our manufacturing process is robust and reproducible – manufacturing qualities that are highly embraced by the FDA.”PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner
Hepion Pharmaceuticals (HEPA) Soars 38% On Solid Date For CRV431
The first one to consider is Hepion Pharmaceuticals Inc (NASDAQ:HEPA), which made a major announcement yesterday and saw its stock soar on the back of the news. Yesterday the company produced highly positive results from the animal study of CRV431, which is its lead candidate. The medicine, which meant for the treatment of liver cirrhosis emanating from aggressive liver diseases, managed to prevent such development in rats.
The company stated that the findings from the study indicate the ‘tremendous potential’ of CRV431 as a medicine and it was not a surprise that the market thought so as well. The stock rallied by as much as 38% following the news.
Mersana Therapeutics (MRSN) is Up 80% in November
The other biotech stock that is worth watching is the Mersana Therapeutics Inc (NASDAQ:MRSN) stock, which has displayed steady growth throughout the year so far. In 2019 along, the stock has gained as much as 80% and earlier on in November the company had another important breakthrough.
The company is developing antibody-drug conjugates in order to treat different forms of cancers and Mersana presented the data at the 34th Annual Meeting of the Society for Immunotherapy of Cancer. It is an important industry event and it took place from November 6 to 10. This development was another reason behind another rally in the stock in recent days.
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.
2 Biotech Stocks To Watch Before Next Week
Biotech has been one of the hottest sectors to invest in for quite a few years. Nowadays, investors are almost always on the lookout for the next big thing from among those stocks. However, when it comes to identifying stocks, an investor needs to do his fair share of research and then decide on his next course of action.
Additionally, one could also watch the market closely and keep track of the latest movements in penny stocks in order to identify potential winners. Here is a look at two biotech stocks which could be of interest to investors.
Biotech Stocks To Watch: Marinus Pharmaceuticals
The first biotech stock to bring under consideration is Marinus Pharmaceuticals Inc (NASDAQ:MRNS) which has made significant gains on Wednesday on the back of an important announcement.
On Wednesday, the company announced that it is going to make a simultaneous public offering of its common stock and private placement. The total value of these two offerings is going to be $65 million. The news resulted in a 38% bump in the stock price in yesterday’s trading session.
Earlier this week, the company announced that it has started its Phase 2 trial for its product ganaxolone as well. The medicine in question is supposed to treat tuberous sclerosis complex and it goes without saying that it is a significant milestone for Marinus.
Biotech Stocks To Watch: Diffusion Pharmaceuticals
The other biotech stock that could be worth tracking is that of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN). The company announced positive data with regards to the Phase 3 study its product Trans Sodium Crocetinate (TSC) plus standard of care (SOC). The data showed that there was an improvement in the condition of patients suffering from inoperable glioblastoma multiforme.
It proved to be a major trigger for the Diffusion stock and after the announcement was made on Tuesday, the stock has rallied by as much as 31.40%. It is a stock that could be worth watching over the coming days.
StockPrice.com Subscribers WIN BIG!
We owe you a BIG congratulations. The whole point of StockPrice.com is to bring you important information, first. Sure we send emails out every day on top trending articles and news but we also bring periodic reports on certain companies.
Earlier this year we brought you a full report on a company, PharmaCyte Biotech (PMCB).
Since that report, we’ve watched as PharmaCyte evolved into what it has become today: a biotech powerhouse on the verge of presenting its treatment to the FDA!
Stock Price Subscribers Saw The Full PMCB 90%+ Breakout From August – December; Congratulations! Click Here to Read Our Original Report
This is a great thing for subscribers and we’ve got more featured reports coming! How do you get these reports first?
STEP 1: Make Sure Our Email Address Is In Your Whitelist Address Book So Nothing Gets Lost In Spam
STEP 2:Take Out Your Cell Phone And Text “STOCKPRICE” to 63566. Even If You Miss An Email, We Send Out Updates Directly To Your Cell Phone In Real Time
Again, congratulations to everyone and make sure you stay tuned for our next Stock Price Exclusive Report!
Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE
Are These Biotech Stocks To Buy Or Sell Right Now?
2 Biotech Stocks Rally But Can That Continue?
One of the sectors that have proven to be a consistently steady performer in the stock market over the past few years is the biotech sector. Hence, it is not really a surprise that investors are almost always on the lookout for the next big thing among biotech stocks.
However, it is important to note that even though biotech is a prosperous sector, an investor needs to put in his fair share of research in order to discover potential winners. Here is a look at two biotech stocks that could be tracked by investors closely over the coming days.
Vistagen Therapeutics Gains As FDA Grants fast track designation for PH94B
The first one to consider is that Vistagen Therapeutics Inc (VTGN Stock Report) that made significant gains after the company made a major announcement with regards to one of its products. The company announced on Tuesday that its social anxiety disorder product PH94B has been granted fast track designation by the United States Food and Drug Administration.
As everyone knows, it is a significant milestone for the company as it tries to bring the product to the market and the market naturally reacted positively to the news. The stock shot up by as much as 44.60% on the back of the news and has emerged as one of the biotech stocks that could be tracked closely today.
Iterum Therapeutics up 280% in 3 Weeks
The other biotech stock that has made a significant move this morning is that of Iterum Therapeutics PLC (NASDAQ:ITRM). On Tuesday, the stock rallied by as much as 22% but there was no material news with regards to the company that could have triggered that sort of a rally. However, last month, the company had made a major announcement about one of its products.
Iterum announced that it had completed enrolment of patients for the study of Sulopenem for Resistant Enterobacteriaceae (SURE). The medicine meant for treating complicated urinary tract infections. The stock has rallied by as much as 270% since the news broke back on November 18.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Biotechnology1 week ago
3 Pharma Stocks To Watch In December 2019
Entertainment2 weeks ago
Is It Time To Buy Or Sell Netflix; Streaming Wars Heat Up
Entertainment2 weeks ago
Disney (DIS) Streaming Business is Getting 1 Million Subscribers a Day
Featured2 weeks ago
Stock Price Black Friday Newsletter – November 29, 2019
Featured2 weeks ago
Stock Price Monday Morning Update – December 2, 2019
Newsletter1 week ago
Stock Price Thursday Morning Update – December 5, 2019
Featured7 days ago
Stock Price Newsletter – December 6, 2019
Featured1 week ago
Stock Price Newsletter – December 3, 2019